Search for Clinical Trial Results

Sponsored By

Membranoproliferative Glomerulonephritis - 6 Studies Found

Status Study
Active, not recruiting Study Name: Eculizumab in Primary MPGN
Condition: Membranoproliferative Glomerulonephritis
Date: 2014-03-17
Interventions: Drug: Eculizumab Other Name: Soliris
Not yet recruiting Study Name: Daratumumab in Treatment of PGNIMD and C3 GN
Condition: Membranoproliferative Glomerulonephritis
Date: 2017-03-20
Interventions: Drug: Daratumumab Open-label Other Name: Darzalex
Completed Study Name: Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Condition: Glomerulonephritis, Membranoproliferative
Date: 2006-01-10
Interventions: Drug: Rituximab The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses
Completed Study Name: Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Condition:
  • Dense Deposit Disease
  • Membranoproliferative Glomerulonephritis<
    Date: 2010-10-13
    Interventions: Drug: Eculizumab 900 mg IV once a week x 4 weeks, 1200 mg
Not yet recruiting Study Name: A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN
Condition:
  • C3 Glomerulonephritis
  • Dense Deposit Disease
  • Dense Deposit Disease
  • Membranoproliferative Glomerulonephritis
    Date: 2013-01-29
    Interventions: Drug: CDX-1135 Other Names:
    • TP10
    • sCR1